Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy

Yokota, Chisato; Kagawa, Naoki; Takano, Koji; Chiba, Yasuyoshi; Kinoshita, Manabu; Kijima, Noriyuki; Oji, Yusuke; Oka, Y.; Sugiyama, Haruo; Tsuboi, Akihiro; Izumoto, Shuichi; Kishima, Haruhiko; Hashimoto, Naoya

doi:10.1007/s00262-021-02954-z

Cited by 6 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initially identified as a tumor suppressor, the Wilms’ tumor 1 (WT1) gene has been shown to display significant increases in expression across a range of human cancers, including lung and pancreatic cancer [ 26 , 27 ]. In turn, high levels of WT1 mRNA have been reported in gliomas at advanced clinical stages and with poor prognoses [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy

Cao,

Lan,

et al. 2024

Aging

View full text Add to dashboard Cite

The telomerase reverse transcriptase promoter (TERTp) is frequently mutated in gliomas. This study sought to identify immune biomarkers of gliomas with TERTp mutations. Data from TCGA were used to identify and validate survival-associated gene signatures, and immune and stromal scores were calculated using the ESTIMATE algorithm. High stromal or immune scores in patients with TERTp-mutant gliomas correlated with shorter overall survival compared to cases with low stromal or immune scores. Among TERTp-mutant gliomas with both high immune and high stromal scores, 213 commonly shared DEGs were identified. Among 71 interacting DEGs representing candidate hub genes in a PPI network, HOXC6, WT1, CD70, and OTP showed significant ability in establishing subgroups of high- and low-risk patients. A risk model based on these 4 genes showed strong prognostic potential for gliomas with mutated TERTp, but was inapplicable for TERTp-wild-type gliomas. TERTp-mutant gliomas with high-risk scores displayed a greater percentage of naïve B cells, plasma cells, naïve CD4 T cells, and activated mast cells than low-risk score gliomas. TIDE analysis indicated that immune checkpoint blockade (ICB) therapy may benefit glioma patients with TERTp mutations. The present risk model can help predict prognosis of glioma patients with TERTp mutations and aid ICB treatment options.

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy

Cao,

Lan,

et al. 2024

Aging

View full text Add to dashboard Cite

show abstract

“…Peptide vaccines are known as effective candidates for glioma immunotherapy, because they can be used for specific targets in cells such as mutated and overexpressed genes and result in improved prognosis in malignant glioma [30,31]. The previous studies showed that targeting key oncogenes in malignant gliomas as an effective immunotherapy method for longer survival duration and higher OS rate while mild adverse effects are observed after vaccination [32].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis

Amanzadeh Jajin,

Oraee Yazdani,

Zali

et al. 2024

Oncol.Rev.

View full text Add to dashboard Cite

Background:Malignant gliomas are known with poor prognosis and low rate of survival among brain tumors. Resection surgery is followed by chemotherapy and radiotherapy in treatment of gliomas which is known as the conventional treatment. However, this treatment method results in low survival rate. Vaccination has been suggested as a type of immunotherapy to increase survival rate of glioma patients. Different types of vaccines have been developed that are mainly classified in two groups including peptide vaccines and cell-based vaccines. However, there are still conflicts about which type of vaccines is more efficient for malignant glioma treatment.Methods:Phase Ⅰ/Ⅱ clinical trials which compared the efficacy and safety of various vaccines with conventional treatments were searched in databases through November 2022. Overall survival (OS) rate, progression free survival (PFS), and OS duration were used for calculation of pooled risk ratio (RR). In addition, fatigue, headache, nausea, diarrhea, and flu-like syndrome were used for evaluating the safety of vaccines therapy in glioma patients.Results:A total of twelve articles were included in the present meta-analysis. Comparison of OS rate between vaccinated groups and control groups who underwent only conventional treatments showed a significant increase in OS rate in vaccinated patients (I2 = 0%, RR = 11.17, 95% CI: 2.460–50.225). PFS rate was better in vaccinated glioma patients (I2 = 83%, RR = 2.87, 95% CI: 1.63–5.03). Assessment of safety demonstrated that skin reaction (I2 = 0.0%, RR = 3.654; 95% CI: 1.711–7.801, p-value = 0.0058) and flu-like syndrome were significantly more frequent adverse effects win vaccinated groups compared to the control group. Subgroup analysis also showed that vaccination leads to better OS duration in recurrent gliomas than primary gliomas, and in LGG than HGG (p-value = 0). On the other hand, personalized vaccines showed better OS duration than non-personalized vaccines (p-value = 0).Conclusion:Vaccination is a type of immunotherapy which shows promising efficacy in treatment of malignant glioma patients in terms of OS, PFS and duration of survival. In addition, AFTV, peptide, and dendritic cell-based vaccines are among the most efficient vaccines for gliomas. Personalized vaccines also showed considerable efficacy for glioma treatments.

show abstract

“…Peptide vaccines can induce antitumor immune responses by using small tumor‐specific antigen sequences. Some peptide vaccines have achieved promising results in the study of malignant glioma, such as rindopepimut (EGFRvIII), R132H (IDH1), and Wilms tumor 1 (WT1) peptide vaccine 85–88 …”

Section: Current Status Of Glioma Therapiesmentioning

confidence: 99%

Oncolytic viral therapy as promising immunotherapy against glioma

Hu,

Tian,

et al. 2023

MedComm – Future Medicine

View full text Add to dashboard Cite

Glioma is a common primary central nervous system malignant tumor in clinical, traditional methods such as surgery and chemoradiotherapy are not effective in treatment. Therefore, more effective treatments need to be found. Oncolytic viruses (OVs) are a new type of immunotherapy that selectively infects and kills tumor cells instead of normal cells. OVs can mediate antitumor immune responses through a variety of mechanisms, and have the ability to activate antitumor immune responses, transform the tumor microenvironment from “cold” to “hot,” and enhance the efficacy of immune checkpoint inhibitors. Recently, a large number of preclinical and clinical studies have shown that OVs show great prospects in the treatment of gliomas. In this review, we summarize the current status of glioma therapies with a focus on OVs. First, this article introduces the current status of treatment of glioma and their respective shortcomings. Then, the important progress of OVs of in clinical trials of glioma is summarized. Finally, the urgent challenges of oncolytic virus treatment for glioma are sorted out, and related solutions are proposed. This review will help to further promote the use of OVs in the treatment of glioma.

show abstract

Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy

Cited by 6 publications

References 37 publications

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy

Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis

Oncolytic viral therapy as promising immunotherapy against glioma

Contact Info

Product

Resources

About